TNFRSF17 and plasma cell myeloma: Considering the various advantages of aptamers over antibodies, Catuogno et al. selected a 2′Fluoro-Pyrimidine modified RNA aptamer, apt69.T, that could effectively bind to BCMA-enriched myeloma cells with excellent serum stability.